|Description||Indeglitazar is a peroxisome proliferator-activated receptor (PPAR) pan-agonist. Phase II clinical trials for Type 2 diabetes mellitus was discontinued.|
|Solubility||Soluble in DMSO|
|Application||Type 2 diabetes mellitus|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator Plexxikon|
SR 1664 is a PPARγ (peroxisome proliferator-activated receptor γ ) inhibitor. SR 1664 can block PPARγ by cyclin-dependent kinase 5 with an IC50 value of 80 nM a...
Oleuropein is a polyphenol found in olive leaves and fruits. Oleuropein displays antioxidant, anti-ischemic and hypolipidemic activity. It has an antagonistic e...
Bezafibrate (marketed as Bezalip and various other brand names) is a fibrate drug used for the treatment of hyperlipidaemia. It helps to lower LDL cholesterol a...
BM152054, a thiazolidinedione, revealed to be potent PPARg-activators in transient transfection assays in vitro.
JW74 is a tankyrase-specific inhibitor. JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines. At the molec...
Ciprofibrate is a peroxisome proliferator-activated receptor agonist.
Seladelpar is a selective peroxisome proliferator-activated receptor -δ receptor agonist. Phase II clinical trials for the treatment of Hyperlipidaemia, Hyperli...
FH535 is a Wnt/β-catenin signaling inhibitor and also a dual PPARγ and PPARδ antagonist.
Arhalofenateis, also known as JNJ-39659100 and MBX102, as an uricosuric agent it is a selective, partial PPAR-γ agonist.
FH535 sodium salt is a dual inhibitor of peroxisome proliferator-activated receptor (PPAR) and Wnt/β-catenin/TCF/LEF signaling. FH535 inhibits recruitment of th...
GSK-3787 is a potent and selective ligand for PPARdelta with good pharmacokinetic properties.
Pioglitazone HCl is a hydrochloride salt form of pioglitazone which is a cytochrome P450 (CYP)2C8 and CYP3A4 enzymes inhibitor for CYP2C8, CYP3A4 and CYP2C9 wit...
LY518674, a phenoxypropionic acid derivative, is a Potent and selective PPAR-alpha agonist produced a dose-dependent increase in serum HDL-c, resulting in 208 +...
Inolitazone is an orally bioavailable PAPR-gamma inhibitor with potential antineoplastic activity. Inolitazone binds to and activates peroxisome proliferation-a...
GW-9820 is a PPAR-gamma agonist with potential antidiabetic effect.
CC-618 has been found to be a PPARβ/δ antagonist that could be used to study the potential biological activity of Cys249 at some extent. IC50: 10 μM.
GW0742 is a potent and highly selective PPARβ/δ agonist, with IC50 of 1 nM, with 1000-fold selectivity over hPPARα and hPPARγ.
Fenofibrate (Tricor, Trilipix) is a compound of the fibrate class and fibric acid derivative.It is used alone or along with statins in the treatment of hypercho...
Elafibranor is a dual PPARα/δ agonist. Elafibranor increases plasma HDL and expression of Acox1, a PPARα target gene, and decreases plasma triglycerides and tot...
Clofibrate is a fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia.